1 patient out of 3 is not 100%. I was merely highlighting the fact the response was observed in AML... On that train of thought, the trial has been a total failure with a no CRs in solid tumours...
I was also correct in my initial statement that the response was observed in R/R AML (harder to treat - better result).
It wasn't even a statement on the specifics of the trial results - merely highlighting the fact that the results were presented during a trading suspension to the detriment of shareholders and the benefit of insiders. That should be your focus.
CHM Price at posting:
0.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)